Pharmacists can help prevent lipoid pneumonia: Two case reports
Journal of the American Pharmacists Association : Japha
|July 18, 2017
Summary
Lipoid pneumonia, an inflammatory lung condition, can result from aspirating lipid-containing substances like mineral oil or ointments. Pharmacists play a key role in identifying risk factors and preventing this condition.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Lipoid pneumonia is an inflammatory lung condition characterized by lipid deposition in the alveoli.
- Exogenous lipoid pneumonia arises from inhaling or aspirating lipid-rich substances, with mineral oil being a common culprit.
Observation:
- Two cases of lipoid pneumonia are presented, highlighting the link to over-the-counter (OTC) products.
- Case 1 involved intranasal application of a mentholated topical ointment.
- Case 2 was linked to mineral oil ingestion for constipation.
Findings:
- The Naranjo algorithm suggested a possible causal link between OTC lipid-containing agents and lipoid pneumonia in both cases.
- Aspiration of intranasal ointments and ingested mineral oil were identified as potential risk factors.
Implications:
- Pharmacists are crucial in preventing lipoid pneumonia by screening patients for lipid-based OTC and cosmetic product use during medication reconciliation.
- Identifying patients at risk and educating them about potential dangers of certain products is essential for early diagnosis and prevention.
Related Concept Videos
01:26Pharmaceutical Poisoning: Potential Scenarios
39
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
39
01:28Pneumonia IV: Management
890
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
890
01:30Pneumonia V: Nursing management and Prevention
3.7K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.7K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
381
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
381
01:30Pneumonia III: Complications and Assessment
977
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
977
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54